Skip to main content
Log In
Sign Up
Home
Stocks
Stock Screener
Stock Exchanges
Comparison Tool
Earnings Calendar
By Industry
Stock Lists
Top Analysts
Top Stocks
Corporate Actions
IPOs
Recent IPOs
IPO Calendar
IPO Statistics
IPO News
IPO Screener
ETFs
ETF Screener
Comparison Tool
New Launches
ETF Providers
News
Trending
Articles
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After Hours
Market Newsletter
Stock Analysis Pro
Watchlist
Collapse
Home
»
Analysts
»
James Gordon
James Gordon
Stock Analyst at JP Morgan
(1.78)
# 2,005
Out of 4,667 analysts
7
Total ratings
80%
Success rate
17.29%
Average return
Main Sectors:
Healthcare
Top Industries:
Biotechnology
Stocks Rated by James Gordon
Stock
Action
Price Target
Current
Upside
Ratings
Updated
ARGX
argenx SE
Maintains:
Overweight
$640
→
$670
$591.82
+13.21%
5
Nov 4, 2024
GMAB
Genmab
Downgrades:
Neutral
n/a
$20.45
-
1
Aug 20, 2024
FGEN
FibroGen
Upgrades:
Neutral
n/a
$0.35
-
1
Apr 7, 2021
ARGX
argenx SE
Nov 4, 2024
Maintains:
Overweight
Price Target:
$640
→
$670
Current: $591.82
Upside:
+13.21%
5 Ratings
View All
GMAB
Genmab
Aug 20, 2024
Downgrades:
Neutral
Price Target:
n/a
Current: $20.45
Upside: -
1 Ratings
View All
FGEN
FibroGen
Apr 7, 2021
Upgrades:
Neutral
Price Target:
n/a
Current: $0.35
Upside: -
1 Ratings
View All